1
|
De Cesare A, Di Cristofano C, Di Filippo AR, Salesi N, Spaziani M, Picchio M, Spaziani E. Total thyroidectomy associated to chemotherapy in primary squamous cell carcinoma of the thyroid. Clin Ter 2019; 170:e231-e234. [PMID: 31304506 DOI: 10.7417/ct.2019.2138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignant disease with rapid fatal prognosis. The onset is generally characterized by sudden bilateral latero-cervical lymphadenopathy. The Authors report patient of 58-year-old who referred for evaluation of rapidly aggravating bilateral latero-cervical lymphadenopathy. The US highlighted the presence of a hypoechoic nodular lesion characterized by peri and intra-nodular vascularization. Multilayer CT showed diffused involvement of mediastinal and bilateral latero-cervical lymph nodes, with no evidence of primary pulmonary neoplasia or elsewhere. The patient underwent total thyroidectomy. The peri-isthmic tissue was removed due to the presence of a small roundish formation, that was due to lymph node metastasis at histological examination. Histological diagnosis: PSCCT. The immunohistochemical panel of the thyroid lesion was indispensable for the differential diagnosis between PSCCT, medullary carcinoma, anaplastic carcinoma, and thyroid metastasis of neoplasia with unknown primitiveness. The patient underwent chemotherapeutic treatment with Carboplatin and Paclitaxel with modest improvement of dysphagia symptoms and reduction of 10-15% of the target lesions. The clinical course was characterized by loco-regional progression of the disease with exitus in 10 months after diagnosis. Survival and quality of life after surgical therapy and chemotherapy were like that of patients undergoing only chemotherapy. Due to the extreme rarity of the neoplasia, 60 cases described in Literature, no exclusive guidelines are reported for PSCCT. More extensive case studies are needed to evaluate the effects of total thyroidectomy with intent R0/R1 on improving survival and quality of life of patients with PSCCT.
Collapse
Affiliation(s)
- A De Cesare
- Department of Surgery, "Pietro Valdoni", Sapienza University of Rome
| | - C Di Cristofano
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Terracina, Latina
| | - A R Di Filippo
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Terracina, Latina
| | - N Salesi
- Department of Oncology, Hospital "S. Maria Goretti", Latina; 4Department of Surgery, "P. Colombo" Hospital, Velletri, Rome, Italy
| | - M Spaziani
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Terracina, Latina
| | | | - E Spaziani
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Terracina, Latina
| |
Collapse
|
2
|
Spaziani E, Picchio M, Di Filippo A, Francioni P, Bonucci M, Salesi N, Narilli P. Challenging differential diagnosis between lipoma and well-differentiated liposarcoma in the retroperitoneum. A case report. Clin Ter 2016; 167:e38-41. [PMID: 27212576 DOI: 10.7417/ct.2016.1923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Liposarcomas are the most common type of sarcomas arising in the retroperitoneum. Retroperitoneal lipomas are extremely rare. They should be distinguished from well-differentiated liposarcomas in order to provide the appropriate treatment. A 53-years-old male was admitted with the presence of a palpable mass in the upper abdomen. Contrast enhanced computerized tomography (CT) of the abdomen and pelvis showed a 20x12 cm mass arising in the retroperitoneum and inglobing the celiac and superior mesenteric trunks. Because of unresectability an open surgical biopsy was performed. Histological examination showed the presence of adipose tissue with diffuse liponecrosis without definitive features of neoplasia. At six-month follow-up a CT documented an increase of the tumor to 22x13 cm. The mass was stable at the CT, performed at 1-year follow-up. Given the impossibility to distinguish well-differentiated liposarcomas from lipomas and the in the present case of unresectable retroperitoneal mass, an observational follow-up was a justified.
Collapse
Affiliation(s)
- E Spaziani
- Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Polo Pontino, Latina
| | - M Picchio
- Department of Surgery, Hospital "P.Colombo", Velletri, Rome
| | - A Di Filippo
- Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Polo Pontino, Latina
| | - P Francioni
- Department of Radiology, Hospital "A. Fiorini", Terracina, Latina
| | - M Bonucci
- Service of Anatomic Pathology and Diagnostic Cytology , "Nuova Itor" Clinic, Roma
| | - N Salesi
- Department of Oncology, Hospital "S. Maria Goretti", Latina
| | - P Narilli
- Division of Surgery, "Nuova Itor" Clinic, Roma, Italy
| |
Collapse
|
3
|
Busco S, Sperduti I, Pistillucci G, Cirino C, Salesi N, Sciacca V, Di Cocco B, Ciorra A, Di Palma T, Rossi R, Calabretta F, Cardillo F, Fattoruso S, Fiori M, Burchi D, Pannozzo F, Albertoni F, Veltri E. Evaluation of diagnostic investigations used in breast cancer patients resident in Latina province during three years follow up after diagnosis. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Scelzi E, Bernardi D, Bonciarelli G, Salesi N, Frassoldati A, Maisano R, Tagliaferri P, Gamucci T, Mencoboni M, Raggi T, Rosti G. Biosimilar epoetin alfa in the management of chemotherapy-induced aneamia: results from ANEMONE observational study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv346.29] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Gascon P, Tesch H, Verpoort K, Rosati M, Salesi N, Barker H, Agrawal S, Muenzberg M, Turner M. Use of Biosimilar G-CSF for Prevention of Chemotherapy-Induced Neutropenia: Pooled Analysis of Clinical Usage Studies. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34101-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
6
|
Di Cocco B, Colonna M, Salesi N, Moscato M, Calogero A, Pacini L, Veltri E. EGFR and K-ras status and clinical outcomes in patients with advanced NSCLC treated with erlotinib: Our experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Salesi N, Colonna M, Di Cocco B, Moscato M, Calogero A, Pacini L, Veltri E. Paclitaxel with bevacizumab (PB) as first-line therapy for metastatic breast cancer: Our experience. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Salesi N, Russillo M, Marandino F, Ruggeri EM, Metro G, Cognetti F, Fabi A. Bone of the hands as unusual metastastatic site of renal cell carcinoma. J Exp Clin Cancer Res 2007; 26:595-597. [PMID: 18365558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Metastases to the bones of the hands and feet (acrometastases) represent an uncommon site of recurrence of renal cell carcinoma (RCC). Although challenging, the prompt recognition of solitary acrometastasis from RCC is of crucial importance, since surgical resection of the acrometastasis in the absence of active systemic disease has been reported as beneficial for a subgroup of patients with RCC. Here, we report the case of a patient with RCC metastatic to the left index finger treated with surgical resection of the acrometastasis who shortly thereafter developed progressive disease despite such an aggressive surgical approach.
Collapse
Affiliation(s)
- N Salesi
- Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
9
|
Salesi N, Pistilli R, Marcelli V, Govoni FA, Di Cocco B, Pacetti U, Di Fonso C, Ciorra A, Natali M, Veltri E. Bisphosphonates and oral cavity avascular bone necrosis: A review of 12 cases. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.18628] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18628 Background: Intravenous bisphosphonates are the current standard of care for the treatment of hypercalcemia of malignancy and for the prevention of skeletal complications associated with bone metastases. Generally, the i.v. administration of bisphosphonates is well tolerated. Recently, retrospective case studies have reported an association between long-term bisphosphonate therapy and osteonecrosis of the jaws. Methods: We reviewed data for 12 patients referred to either an oral and maxillofacial surgeon or an oral medicine specialist for the management of clinically apparent chronic oral osteonecrosis of unknown etiology. All had received therapy cancer-related simultaneously with bisphosphonate management. Results: Typical presenting symptoms were pain and exposed bone at the site of a previous tooth extraction. In most patients, lesions initially occurred after dental extraction or other odontostomatological procedures, and 5 had a spontaneous event. Biopsy of the involved area showed the presence of necrotic lacunae, with infiltration of lymphocytes and histiocytes. In 9 cases, histological or cytological diagnosis of suspicious osteomyelitis was done. There was no observed correlation of the intraoral lesions with myelosuppression secondary to antineoplastic therapy. Conclusions: Based on these patients’ respective histories, clinical presentations, and responses to surgical and antibiotic treatments, it appears that the pathogenesis of this osteonecrotic process is most consistent with localized vascular insufficiency. In our opinion, the mechanism by which bisphosphonates could compromise bone vascularity may be related to its effect on the osteoclasts. The potent bisphosphonate mediated inhibition of osteoclast function serves to decrease bone resorption and inhibit normal bone turnover remodeling, resulting in microdamage accumulation and a reduction in some mechanical properties of bone. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Salesi
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - R. Pistilli
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - V. Marcelli
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - F. A. Govoni
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - B. Di Cocco
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - U. Pacetti
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - C. Di Fonso
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - A. Ciorra
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - M. Natali
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| | - E. Veltri
- Lega Italiana per la Lotta Contro i Tumori, A. Fior, Terracina, Italy; S. Filippo Neri Hospital, Rome, Italy; A. Fiorini Hospital, Terracina, Italy; La Sapienza University, Rome, Italy; L. Di Liegro Hospital, Gaeta, Italy; M. Goretti Hospital, Latina, Italy
| |
Collapse
|
10
|
Fabi A, Salesi N, Di Cocco B, Vidiri A, Visca P, Pace A, Carapella C, De Paula U, Mirri A, Cognetti F. Choroid plexus carcinoma in the adult: is there a role for chemotherapy? J Exp Clin Cancer Res 2005; 24:493-6. [PMID: 16270538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Choroid plexus carcinoma is a rare primary brain neoplasm arising from epithelial differentiated tissue, originating from the choroids plexus of the ventricles and, in 90% of the cases, in the lateral and fourth ventricles. This neoplasm is seen mainly in children and reported infrequently in adults. The treatment of choroid plexus carcinoma is based on scarce evidence in literature. We report a rare case of an adult woman affected by a choroid plexus tumour and a discussion on the therapeutic management of this uncommon adult malignancy.
Collapse
Affiliation(s)
- A Fabi
- Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Terzoli E, Fabi A, Bria E, Giannarelli D, Cuppone F, Vici P, Salesi N, Astorre P, Cognetti F, Nisticò C. Delayed antiemetic treatment for weekly chemotherapy: Overview of 275 patients enrolled in 6 phase II trials of vhemotherapy in metastatic breast vancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Terzoli
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - A. Fabi
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - E. Bria
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - D. Giannarelli
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - F. Cuppone
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - P. Vici
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - N. Salesi
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - P. Astorre
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - F. Cognetti
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| | - C. Nisticò
- Regina Elena National Cancer Institute, Rome, Italy; Policlinico Militare, Rome, Italy
| |
Collapse
|
12
|
Salesi N, Carlini P, Ruggeri EM, Ferretti G, Bria E, Cognetti F. Prostate cancer: the role of hormonal therapy. J Exp Clin Cancer Res 2005; 24:175-80. [PMID: 16110748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Prostate cancer is the cause of more than 1% of all deaths in men. Its incidence is increasing by 2-3% per year. The general prognosis for diagnosed prostate cancer remains poor, with 70% survival at 10 years compared to the general population. About 50% of the cases are diagnosed at a locally advanced stage, and about 30% have bone metastases at the time of diagnosis. Adjuvant systemic treatments (hormones or chemotherapy), which are effective for advanced-stage disease, might have a greater role in early-stage disease. Advanced prostate cancer is an incurable disease. Treatment objective is palliation only. Here, we review the major controversies concerning hormonal therapy, and provide a general approach to management of patients with early-stage and advanced prostate cancer.
Collapse
Affiliation(s)
- N Salesi
- Dept. of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
| | | | | | | | | | | |
Collapse
|
13
|
Ferretti G, Bria E, Carlini P, Felici A, Giannarelli D, Ciccarese M, Cecere FL, Salesi N, Di Cocco B, Cognetti F. Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - E. Bria
- Regina Elena Cancer Institute, Rome, Italy
| | - P. Carlini
- Regina Elena Cancer Institute, Rome, Italy
| | - A. Felici
- Regina Elena Cancer Institute, Rome, Italy
| | | | | | | | - N. Salesi
- Regina Elena Cancer Institute, Rome, Italy
| | | | | |
Collapse
|
14
|
Fabi A, Ferretti G, Salesi N, Papaldo P, Carlini P, Ciccarese M, Di Cocco B, Cecere F, Nardoni C, Felici A, Cognetti F. Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients? Ann Oncol 2005; 16:516-7. [PMID: 15642705 DOI: 10.1093/annonc/mdi078] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Fabi A, Papaldo P, Ciccarese M, Salesi N, Lorusso V, Ferretti G, Carlini P, Sacchi I, Cecere F, Cognetti F. Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: A phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.813] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Fabi
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - P. Papaldo
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - M. Ciccarese
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - N. Salesi
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - V. Lorusso
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - G. Ferretti
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - P. Carlini
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - I. Sacchi
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - F. Cecere
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| | - F. Cognetti
- Regina Elena National Cancer Institute, Rome, Italy; Oncology Institute, Bari, Italy
| |
Collapse
|
16
|
Di Cocco B, Calabretta F, Alghisi F, Salesi N, Bossone G. [Tumor markers in epithelial ovarian cancer]. Minerva Ginecol 2003; 55:327-32. [PMID: 14581857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Many circulating markers are already in clinical practice and in experimental use for the diagnosis, therapeutic monitoring, and in the follow-up of ovarian cancer. The cancer antigen-125 (CA-125) has shown to be useful in epithelial ovarian cancer, but its specificity is too low for the test to be used as a primary screening technique in early stage and particularly in premenopausal women. In the last few years, several studies have focused on using the serial measurement of complementary serum markers to improve the positive predictive value and diagnostic accuracy. The main problem is that the different cellular lines express these markers in a very variable way.
Collapse
Affiliation(s)
- B Di Cocco
- Divisione di Oncologia Medica, Azienda Ospedaliera S.Andrea, Roma, Italy
| | | | | | | | | |
Collapse
|
17
|
Salesi N, Bossone G, Della Longa G, Di Cocco B. [A new drug in the therapy of chronic myeloid leukemia: ST1571]. Minerva Med 2003; 94:71-6. [PMID: 12858155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
The therapy of chronic myeloid leukemia, characterized by the presence of the Philadelphia chromosome in the clonal hematopoietic stem cells, has changed dramatically in the last years with the development of a specific inhibitor of the BCR-ABL tyrosine kinase: tyrosine kinase inhibitor imatinib mesylate (formerly STI571, [Glivec]). Glivec selectively blocks cellular proliferation and induces apoptosis in Philadelphia chromosome-positive (Ph+) cells harbouring the Bcr-Abl tyrosine kinase. Clinical development of imatinib mesylate began with 3 large, multicenter, phase II trials. The majority (88%) of interferon-alpha-resistant or intolerant patients in chronic-phase CML, achieved a complete hematologic response to imatinib mesylate. More importantly, approximately half of the patients achieved a major cytogenetic response, a result historically associated with improved survival. Furthermore, 21% of patients in accelerated-phase CML and 13.5% of patients in blastic-phase CML (patient populations with typically poor prognosis before the advent of imatinib mesylate) achieved major cytogenetic responses.
Collapse
Affiliation(s)
- N Salesi
- Scuola di Specializzazione in Oncologia Medica, II Facoltà di Medicina e Chirurgia, Università degli Studi di Roma La Sapienza, Roma, Italy.
| | | | | | | |
Collapse
|
18
|
Salesi N, Di Cocco B, Alghisi F, Calabretta F, Bossone G. [Testis cancer markers. Clinical use]. Minerva Med 2002; 93:365-9. [PMID: 12410169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
Testis tumour is relatively rare and more frequent between 15-35 years of age. The 90% of this tumour derivates from germinal cells, the remaining cases originate from stromal cells or are secondary lesions from other neoplasms. The present clinical use of serum markers, especially alfa-fetoprotein (AFP), human chorionic gonadotrophin protein (HCG) and serum lactate dehydrogenase (LDH) is examined.
Collapse
Affiliation(s)
- N Salesi
- I Facoltà di Medicina e Chirurgia, Divisione di Oncologia Medica, Azienda Ospedaliera S. Andrea, Rome, Italy
| | | | | | | | | |
Collapse
|
19
|
Lacava V, Salesi N, Ferrone L, Veri A, Lembo R, Masi MC, Rocchi M, Rondinelli R, Parisi E, Grieco T, Balzani A, Clerico R, Innocenzi D, Bottoni U, Calvieri S. [Importance of dermatologic screening within the frame work of a general cancer prevention program]. Minerva Med 2001; 92:85-8. [PMID: 11323570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
BACKGROUND Skin tumours represent about 11% of all the malignant neoplasms and their frequency is increasing annually. Skin tumours (melanoma, basal and squamous cell carcinoma, etc.) can be used for a good screening activity, but in relation to breast or cervix uteri cancer needs to be better defined. A test on a population of selected patients against skin malignant neoplasms has been carried out in our Centre. All of them had skin lesions and further checks were necessary. METHODS The diagnostic protocol used in our Centre for Oncological Prevention uses the collection of anamnestic data and an objective examination. Between 1996 and 2000, 222 patients between the ages of 18 and 80 have been selected. All of them had suspected skin lesions. The patients were selected by the oncologist, particularly for pigmentation, asymmetry, irregular borders and heterogeneous colour of their skin lesions. Subsequently, the patients were sent for a further examination to the dermatologist oncologist, who on the basis of the objective dermatological examination with possible dermatoscopy, made a clinical diagnosis of the skin injuries or suggested surgical removal for the histological control of the same. RESULTS Requested consultations: 222. Exami-nations made: 195. Patients considered: 190. Skin injuries examined: 190. The following skin lesions were identified: melanoma: 4 (2.1%) [2: I Clark level; 2: II Clark level]; basal cell carcinoma: 14 (7.37%); dermatofibrosarcoma: 1 (0.53%); keratoacanthoma: 1 (0.53%); dysplastic nevus: 4 (2.1%); actinic keratosis: 7 (3.68%); benign lesions: 159 (83.68%). CONCLUSIONS These data were obtained by a screening program and it is therefore not a random study. This study shows interesting results because tumoral skin lesions and in particular melanoma were recognised at early stages. This is more than enough for us to create a specific screening program for skin lesions to cut down the rate of morbidity and mortality.
Collapse
Affiliation(s)
- V Lacava
- Dipartimento di Medicina Sperimentale, Università degli Studi La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|